Skip to main content
All lobbying filings

PERSONALIZED MEDICINE COALITION

Lobbying for PERSONALIZED MEDICINE COALITION · Health care

 Filing 3rd Quarter - Report
3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $47,000.00 expenses · posted Oct 20, 2025

Official filing document

 Bills named in this filing 5
  • HR 2471
    Right Drug Dose Now Act of 2025
  • S 832
    EPIC Act of 2025
  • HR 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • HR 946
    ORPHAN Cures Act
  • HR 1672
    Maintaining Investments in New Innovation Act
 Lobbying activity 2
Health Issues

Congressional Personalized Medicine Caucus Genetic Testing and Genomic Sequencing for Rare Diseases H.R. 2471 Right Drug Dose Now Act S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program (CMS-1832-P) Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes (CMS-1833-P) Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs; Overall Hospital Quality Star Ratings; and Hospital Price Transparency (CMS-1834-P) Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community

Budget/Appropriations

FY 2026 Food and Drug Administration Budget Priorities for CDER, CBER and CDRH FY 2026 National Institutes of Health Budget Priorities Reauthorization of the Prescription Drug User Fee Act; PFUFA VIII [FDA-2025-N-0816] Reauthorization of the Medical Device User Fee Act; MDUFA VI [FDA-2025-N-1157]

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem